Stryker Corporation (NYSE:SYK) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Stryker, with 18 buy ratings and six holds among 24 firms. The average 12-month price target is $380.40, well above the stock’s reported $282.06 price.
• Stryker’s latest quarter exceeded expectations, with adjusted earnings of $3.69 per share and revenue of $6.59 billion; revenue rose 9.4% year over year. The company guided to fiscal 2026 earnings of $14.95–$15.10 per share.
• Insiders sold about $118.2 million of shares over the past 90 days, while institutional investors own 77.09% of the stock. Stryker also declared a quarterly dividend of $0.88 per share, implying a 1.2% annual yield.

Stryker Corporation (NYSE:SYK - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-four research firms that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and eighteen have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $380.40.

SYK has been the topic of several analyst reports. Wells Fargo & Company lowered their price target on shares of Stryker from $418.00 to $348.00 and set an "overweight" rating on the stock in a report on Wednesday, September 9th. Raymond James Financial set a $370.00 price objective on shares of Stryker in a research note on Friday, July 31st. UBS Group initiated coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price objective on the stock. Leerink Partners lowered their target price on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research note on Friday, June 5th. Finally, BTIG Research dropped their target price on shares of Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a report on Friday, July 31st.

Insider Buying and Selling

In related news, Director Ronda Stryker sold 50,000 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of the company's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company's stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System boosted its position in Stryker by 30,523.4% in the 2nd quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company's stock valued at $51,443,391,000 after buying an additional 162,861,784 shares during the period. Norges Bank purchased a new stake in shares of Stryker during the fourth quarter worth $1,822,272,000. Bank of America Corp DE purchased a new position in Stryker in the second quarter valued at $1,404,284,000. Auto Owners Insurance Co boosted its holdings in Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the period. Finally, Legal & General Group Plc acquired a new position in Stryker during the 2nd quarter worth $707,212,000. Institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

NYSE:SYK opened at $282.06 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a 50-day simple moving average of $323.77 and a two-hundred day simple moving average of $325.37. The firm has a market capitalization of $108.19 billion, a PE ratio of 29.23, a P/E/G ratio of 1.73 and a beta of 0.76. Stryker has a 52-week low of $267.00 and a 52-week high of $392.55.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the company earned $3.13 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts forecast that Stryker will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker's dividend payout ratio is 36.48%.

About Stryker

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker's principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.